Aromatase Inhibitors in Testosterone Therapy

Mechanism of Action and Clinical Indications

The American College of Endocrinology recommends that aromatase inhibitors like anastrozole be used to prevent excessive conversion of testosterone to estradiol, which can cause gynecomastia, sexual dysfunction, and other adverse effects in men receiving testosterone replacement therapy 1, 2
Aromatase inhibitors reversibly block the enzymatic conversion of testosterone to estradiol, reducing estradiol production while maintaining or increasing testosterone levels through reduced negative feedback on the hypothalamic-pituitary-gonadal axis 1, 2
In men receiving testosterone replacement, aromatase inhibitors decrease estradiol levels from a median of 65 pg/mL to 22 pg/mL (P < 0.001) while maintaining stable testosterone levels (616 ng/dL pre-treatment vs 596 ng/dL post-treatment) 1

The American Society of Clinical Oncology recommends that testosterone/androgen supplementation should not be used by men with breast cancer (moderate strength recommendation) 3, 4
In transgender men receiving gender-affirming testosterone therapy, high concentrations of testosterone may increase risk for estrogen-dependent cancer progression through aromatization, according to the World Professional Association for Transgender Health 5, 6

The Endocrine Society recommends that baseline bone mineral density via DEXA scan and fracture risk assessment are absolute requirements before initiating anastrozole therapy, regardless of the indication 1, 2
Severe osteoporosis (T-score < -4 or >2 vertebral fractures) is an absolute contraindication to anastrozole use, and moderate bone density loss (T-score -1.0 to -2.5) requires extreme caution and consideration of concurrent bone-protective agents 1, 2
Annual bone mineral density monitoring is necessary if continuing long-term therapy 1

The most commonly studied and recommended regimen is anastrozole 0.5 mg three times weekly, which appears safer than daily dosing by limiting excessive estradiol suppression 1, 2
Monitor testosterone levels every 6-12 months while on combined therapy to ensure appropriate hormonal balance 1
Never skip baseline bone density assessment before initiating aromatase inhibitor therapy, as this is a critical safety requirement 1, 2